Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Sage Therapeutics downgraded to Neutral from Buy at Guggenheim » 07:13
01/03/23
01/03
07:13
01/03/23
07:13
SAGE

Sage Therapeutics

$38.10 /

-0.61 (-1.58%)

Guggenheim analyst Yatin…

Guggenheim analyst Yatin Suneja downgraded Sage Therapeutics to Neutral from Buy with no price target.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$38.10 /

-0.61 (-1.58%)

SAGE Sage Therapeutics
$38.10 /

-0.61 (-1.58%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
SAGE Sage Therapeutics
$38.10 /

-0.61 (-1.58%)

Conference/Events
Sage Therapeutics management to meet with Piper Sandler » 04:55
12/15/22
12/15
04:55
12/15/22
04:55
SAGE

Sage Therapeutics

$41.29 /

-0.56 (-1.34%)

Investor luncheon meeting…

Investor luncheon meeting to be held in Boston on December 15 hosted by Piper Sandler.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$41.29 /

-0.56 (-1.34%)

SAGE Sage Therapeutics
$41.29 /

-0.56 (-1.34%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
SAGE Sage Therapeutics
$41.29 /

-0.56 (-1.34%)

Conference/Events
Sage Therapeutics management to meet with Piper Sandler » 16:15
12/11/22
12/11
16:15
12/11/22
16:15
SAGE

Sage Therapeutics

$39.14 /

-0.31 (-0.79%)

Investor luncheon meeting…

Investor luncheon meeting to be held in Boston on December 15 hosted by Piper Sandler.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$39.14 /

-0.31 (-0.79%)

SAGE Sage Therapeutics
$39.14 /

-0.31 (-0.79%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
SAGE Sage Therapeutics
$39.14 /

-0.31 (-0.79%)

Conference/Events
Biogen and Sage Therapeutics to hold a joint investor webcast » 07:50
12/06/22
12/06
07:50
12/06/22
07:50
SAGE

Sage Therapeutics

$43.54 /

-0.05 (-0.11%)

, BIIB

Biogen

$292.64 /

-6.35 (-2.12%)

Biogen and Sage…

Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
BIIB Biogen
$292.64 /

-6.35 (-2.12%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

Hot Stocks
Sage Therapeutics, Biogen complete NDA to FDA for zuranolone » 06:37
12/06/22
12/06
06:37
12/06/22
06:37
SAGE

Sage Therapeutics

$43.54 /

-0.05 (-0.11%)

, BIIB

Biogen

$292.64 /

-6.35 (-2.12%)

Sage Therapeutics (SAGE)…

Sage Therapeutics (SAGE) and Biogen (BIIB) announced the completion of the rolling submission of a New Drug Application to the U.S. FDA for zuranolone in the treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission completes the NDA filing that was initiated earlier this year.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
BIIB Biogen
$292.64 /

-6.35 (-2.12%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

Conference/Events
Biogen and Sage Therapeutics to hold a joint investor webcast » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
SAGE

Sage Therapeutics

$43.54 /

-0.05 (-0.11%)

, BIIB

Biogen

$292.64 /

-6.35 (-2.12%)

Biogen and Sage…

Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
BIIB Biogen
$292.64 /

-6.35 (-2.12%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

Conference/Events
Biogen and Sage Therapeutics to hold a joint investor webcast » 17:13
12/05/22
12/05
17:13
12/05/22
17:13
SAGE

Sage Therapeutics

$43.54 /

-0.05 (-0.11%)

, BIIB

Biogen

$292.64 /

-6.35 (-2.12%)

Biogen and Sage…

Biogen and Sage Therapeutics hold a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, Zuranolone, on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

11/09/22 H.C. Wainwright
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright
11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
BIIB Biogen
$292.64 /

-6.35 (-2.12%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
SAGE Sage Therapeutics
$43.54 /

-0.05 (-0.11%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

BIIB Biogen
$292.64 /

-6.35 (-2.12%)

Recommendations
Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright » 06:12
11/09/22
11/09
06:12
11/09/22
06:12
SAGE

Sage Therapeutics

$33.94 /

+0.025 (+0.07%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$33.94 /

+0.025 (+0.07%)

SAGE Sage Therapeutics
$33.94 /

+0.025 (+0.07%)

11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
06/01/22 Piper Sandler
Sage Therapeutics data better than Street expectations, says Piper Sandler
SAGE Sage Therapeutics
$33.94 /

+0.025 (+0.07%)

Hot Stocks
Sage sees cash and equivalents of $1.3B at end of FY22 » 06:39
11/08/22
11/08
06:39
11/08/22
06:39
SAGE

Sage Therapeutics

$33.92 /

-0.685 (-1.98%)

Sage anticipates cash,…

Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3B at the end of 2022; does not anticipate receipt of any milestone payments from collaborations in 2022; anticipates R&D and SG&A spending to increase as it advances planned and ongoing studies for SAGE-718 and SAGE-324 and prepares for the potential launch of zuranolone; believes its cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
06/01/22 Piper Sandler
Sage Therapeutics data better than Street expectations, says Piper Sandler
SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

Earnings
Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) » 06:37
11/08/22
11/08
06:37
11/08/22
06:37
SAGE

Sage Therapeutics

$33.92 /

-0.685 (-1.98%)

Reports Q3 revenue…

Reports Q3 revenue $1.74M, consensus $1.64M. Cash, cash equivalents and marketable securities as of September 30 were $1.4B compared to $1.5B at June 30. "This has been an important year for Sage, marked by the execution of significant milestones across our franchises. Looking ahead, we remain focused on the completion of the NDA submission for zuranolone in MDD and PPD, and are well into commercialization preparations to support a potential launch. Patients with depression are desperate to find new medicines that are safe, rapid-acting, short course, and have a sustained effect. We believe zuranolone, if approved, has the potential to deliver a new treatment option for patients," said Barry Greene, CEO. "In parallel, our team is advancing multiple clinical studies across our pipeline that span our neuropsychiatry and neurology franchises. I am proud of the tremendous progress our team has made on behalf of patients this year and am energized by the momentum we have going into 2023 and beyond."

ShowHide Related Items >><<
SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

11/01/22 Loop Capital
Sage Therapeutics initiated with a Hold at Loop Capital
08/03/22 Citi
Sage Therapeutics price target lowered to $40 from $41 at Citi
08/02/22 Stifel
Sage Therapeutics price target lowered to $56 from $58 at Stifel
06/01/22 Piper Sandler
Sage Therapeutics data better than Street expectations, says Piper Sandler
SAGE Sage Therapeutics
$33.92 /

-0.685 (-1.98%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.